Dr. Austin Greco, M.D. Internal Medicine - Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1111 Duff Ave, Ames, IA 50010 Phone: 515-239-4401 Fax: 515-239-4791 |
Dr. Venkatesh K. Rudrapatna, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1111 Duff Avenue, Ames, IA 50010 Phone: 515-239-4401 Fax: 515-239-4791 |
Dr. Larry A. Otteman, MD Internal Medicine - Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 1111 Duff Ave, Ames, IA 50010 Phone: 515-239-4401 Fax: 515-239-4791 |
Dr. Joseph James Merchant, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1111 Duff Ave, Ames, IA 50010 Phone: 515-239-4401 Fax: 515-239-4791 |
Dr. Mark Michael Guffy, M.D. Internal Medicine - Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 1111 Duff Ave, Ames, IA 50010 Phone: 515-239-4401 Fax: 515-239-4791 |
News Archive
In the current issue of Family Medicine and Community Health (Volume 6,Number 4, 2018; DOI: https://doi.org/10.15212/FMCH.2018.0118: , Somayeh Zare, Mehdi Kargar, Jeyran Ostovarfar, Mohammad Hossein Kaveh of the Department of the Health Education and Promotion, School of Health, Shiraz University of Medical Science, Shiraz, Iran discuss how studies show that suitable design of educational programs can affect prisoners' awareness of AIDS.
A way to turn off one gene at a time has earned acceptance in biology laboratories over the last decade. Doctors envision the technique, called RNA interference, as a tool to treat a variety of diseases if it can be adapted to humans.
EntreMed, Inc. today announced the initiation of a multi-center Phase 2 study with its lead oncology product candidate, ENMD-2076, in patients with platinum resistant ovarian cancer. The study will be conducted at up to six sites in the United States and Canada. In addition, EntreMed received a No Objection Letter (NOL) from the Therapeutic Products Directorate of Health Canada on its Clinical Trial Application to conduct the Phase 2 clinical trial in ovarian cancer patients.
Triple negative breast cancer (TNBC) is a type of cancer that has none of the three markers that are currently used for targeted chemotherapy. These markers are estrogen receptor (ER), progesterone receptor (PR) and HER2.
› Verified 8 days ago